Robert S. Woodward

Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients

This study sought to determine 1) the incidence and costs of new onset diabetes mellitus (NODM) associated with maintenance immunosuppression regimens following renal transplantation and 2) whether the mode of dialysis pretransplant or the type of calcineurin inhibition used for maintenance immunosuppression affected either the incidence or cost of NODM. The study examined the United States Renal Data Systems clinical and financial records from 1994 to 1998 of all adult, first, single‐organ, renal transplantations in either 1996 or 1997 with adequate financial records. It used the second diagnosis of diabetes in previously nondiabetic patients to identify NODM. While NODM had an incidence of approximately 6% per year among wait‐listed dialysis patients, NODM over the first 2 years post‐transplant had an incidence of almost 18% and 30% among patients receiving cyclosporine and tacrolimus, respectively. By 2 years post‐transplant, Medicare paid an extra

Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital

21 500 per newly diabetic patient. We estimated the cost of diabetes attributable to maintenance immunosuppression regimens to be

Antimicrobial misuse in patients with positive blood cultures

2025 and

Cost-effectiveness of extending medicare coverage of immunosuppressive medications to the life of a kidney transplant

3308 for each tacrolimus patient and

Economic cost of expanded criteria donors in cadaveric renal transplantation: Analysis of medicare payments.

1137 and

The effect of medication compliance on the control of hypertension

1611 for each cyclosporine patient at 1 and 2 years post‐transplant, respectively.

The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation.

Strictly enforced formulary restrictions for aminoglycosides, cephalosporins, and a vancomycin group generated combined savings of

The Incidence and Costs of Sepsis and Pneumonia Before and After Renal Transplantation in the United States

2.61 (p less than 0.0046) per antibiotic day and

Income‐Related Disparities in Kidney Transplant Graft Failures Are Eliminated by Medicare's Immunosuppression Coverage

34,597 (p less than 0.0003) per month. Even after some cost increases (not significant) in new and other antibiotics, the program saved

Cadaveric versus living donor kidney transplantation: A medicare payment analysis.

1.33 (p less than 0.0175) per antibiotic day and